Dose reductions or interruptions may be required to manage treatment-associated adverse events among patients with myelodysplastic syndromes (MDS) treated with lenalidomide; such modifications are recommended to sustain therapy and maximize treatment duration. The aim of this retrospective case-control study was to determine the relationship between lenalidomide dose modification (DM), duration of lenalidomide therapy (DOT), and patient outcomes in patients with MDS. Those patients with database follow-up >20 months (n = 305) were more likely to have received erythropoiesis-stimulating agents (ESAs) (P = 0.004), had longer median DOT (P < 0.001), and higher rate of DM (P < 0.001) versus those with shorter follow-up (n = 306). Multivariate analysis indicated that lenalidomide DM (odds ratio [OR] 1.08) and prior ESA treatment (OR 2.40) were significantly associated with longer follow-up; transfusion dependence before lenalidomide initiation was associated with a significantly shorter follow-up (OR 0.60). These data suggest that effective management of lenalidomide treatment using dose reduction and/or delay is associated with longer DOT, which can improve patient outcomes.
<p>Table S1. Changes in Proportion (%) of γH2AX-Positive Cells in Peripheral Blood upon Veliparib and Veliparib/Temozolomide Treatment Figure S1. FANCD2 monoubiquitination following ex vivo melphalan treatment of patient bone marrow cells Figure S2.Pretreatment levels of PARP1 and MGMT Figure S3.Pretreatment MGMT promoter methylation in patient peripheral blood (PB) or bone marrow (BM) AML cells Figure S4. PARP inhibition in peripheral blood cells</p>
